Bharat Book

Antibiotics Partnering Terms and Agreements

Press Release   •   Dec 10, 2013 10:42 IST

Dec 10, 2013 : Bharat Book Bureau presents the new report, on 'Antibiotics Partnering Terms and Agreements'  report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 150 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table of content :

Chapter 1 – Introduction

Chapter 2 – Trends in antibiotics dealmaking
2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Big pharma antibiotics dealmaking activity
2.4. Big biotech antibiotics dealmaking activity
2.5. Most active in antibiotics partnering
2.6. Antibiotics partnering by deal type
2.7. Antibiotics partnering by disease type
2.8. Partnering by antibiotics technology type
2.9. Partnering by antibiotics stage of development
2.10. Average deal terms for antibiotics partnering
2.10.1 Antibiotics headline values
2.10.2 Antibiotics upfront payments
2.10.3 Antibiotics milestone payments
2.10.4 Antibiotics royalty rates
2.11. The anatomy of antibiotics partnering
2.12. The anatomy of an antibiotics deal
2.12. a. Case study 1: Calixa Therapeutics & Astellas –May 24 2009
2.12.b. Case study 2: Advanced Life Sciences & Wyeth- Oct 1 2008
2.12.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011

Chapter 3 – Leading antibiotics deals
3.1. Introduction
3.2. Top antibiotics deals by value C

Chapter 4 – Big pharma antibiotics deals
4.1. Introduction
4.2. How to use big pharma antibiotics partnering deals
4.3. Big pharma antibiotics partnering company profiles
Baxter International
Bristol-Myers Squibb
Eli Lilly
Forest Laboratories
Merck & Co
Warner Chilcott

For more information kindly visit :

Related link :

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.